Capital increase 2018
Below you find further information about the capital increase that was resolved by the Management Board of OncoRedox with approval of the Supervisory Board on October 7, 2018.
NOTE:
The information contained on this web page is neither
an offer for sale of securities nor solicitation to buy any
securities. This information is not for circulation in the United
States of America (”United States”) or within the United States
(including its territories and dependencies, states and the
District of Columbia) and may not be forwarded or circulated to
“U.S. persons” (as defined in Regulation S under the U.S.
Securities Act of 1933 in its currently applicable form
[“Securities Act”]) or to publications with a general circulation
in the United States. The information contained on this web page
is neither an offer nor a solicitation to buy any securities in
the United States. The securities of OncoRedox have not been and
will not be registered under the provisions of the Securities Act
and may not be offered or sold within the United States or to U.S.
persons without being registered or without the presentation of an
exemption from the registration requirements. There will be no
public offering of securities in the United States, the United
Kingdom, Australia, Canada, Japan or South Africa.
| Notification pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (Wertpapierprospektgesetz) / October 23, 2018 | |
| Result of capital increase – Publication of Inside Information according to Article 17 MAR / October 23, 2018 | |
| Notification pursuant to Section 8 para. 1 sentence 6 of the German Securities Prospectus Act (Wertpapierprospektgesetz) / October 16, 2018 | |
| Subscription price – Publication of Inside Information according to Article 17 MAR / October 16, 2018 | |
| Subscription offer (Please note: Currently there is only a German version available) / October 8, 2018 | |
| Press release / October 8, 2018 | |
| Publication of Inside Information according to Article 17 MAR / October 3, 2018 |
For further information, please don ’t hesitate to contact us:
OncoRedox
Ziegelhäuser Landstraße 3
69120 Heidelberg
Contact:
E-Mail: ir@oncoredox.com
Tel: +49 6221 64924-87